[{"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-001", "question": "A 45-year-old man with autosomal dominant polycystic kidney disease presents with acute flank pain and hematuria. Imaging reveals a 6 cm cyst with internal septations and hemorrhage. Renal function is preserved, but he develops fever and leukocytosis. Blood cultures are negative, but cyst aspiration yields purulent fluid positive for Escherichia coli. Despite appropriate intravenous antibiotics, his symptoms persist. What is the most appropriate next step in management?", "options": ["Switch to a different antibiotic based on sensitivity testing", "Perform percutaneous cyst drainage and sclerotherapy", "Initiate long-term suppressive antibiotic therapy", "Surgical decortication of the infected cyst", "Administer intraparenchymal antibiotic infusion"], "answer": "D", "answer_index": 3, "explanation": "Surgical decortication is indicated for persistent cyst infection in polycystic kidney disease when antibiotics and drainage fail, as it allows complete removal of infected material. Percutaneous drainage often fails due to viscous cyst contents and multiloculation, while sclerotherapy is not appropriate for infected cysts. Long-term suppression or antibiotic switches do not address the source of ongoing infection.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed—the keyed answer (D) is not the best next step. Key stem clues: 45-year-old with ADPKD, 6 cm infected cyst (E. coli positive from aspiration), preserved renal function, persistent symptoms despite IV antibiotics. The clinical problem is a proven infected renal cyst failing medical management. The keyed answer (D, surgical decortication) skips the standard next step of percutaneous drainage with prolonged catheter placement. In ADPKD-associated cyst infections, the management hierarchy is: (1) IV antibiotics with lipophilic agents, (2) percutaneous drainage if antibiotics fail, (3) surgery only if drainage fails or complications arise. The stem states 'despite appropriate IV antibiotics, symptoms persist'—this indicates failure of first-line therapy, making percutaneous drainage (B) the correct next step, not immediate surgery. Surgical decortication is reserved for drainage failures, not as the immediate next intervention. The rationale incorrectly dismisses percutaneous drainage as 'often fails' without acknowledging it must be attempted before surgery. Medical accuracy issue: The management sequence is inverted. Minimal fix: Change the key to B, or add to the stem 'after failed percutaneous drainage' to justify surgical intervention.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed—the keyed answer (D) is not the best next step. Key stem clues: 45-year-old with ADPKD, 6 cm infected cyst (E. coli positive from aspiration), preserved renal function, persistent symptoms despite IV antibiotics. The clinical problem is a proven infected renal cyst failing medical management. The keyed answer (D, surgical decortication) skips the standard next step of percutaneous drainage with prolonged catheter placement. In ADPKD-associated cyst infections, the management hierarchy is: (1) IV antibiotics with lipophilic agents, (2) percutaneous drainage if antibiotics fail, (3) surgery only if drainage fails or complications arise. The stem states 'despite appropriate IV antibiotics, symptoms persist'—this indicates failure of first-line therapy, making percutaneous drainage (B) the correct next step, not immediate surgery. Surgical decortication is reserved for drainage failures, not as the immediate next intervention. The rationale incorrectly dismisses percutaneous drainage as 'often fails' without acknowledging it must be attempted before surgery. Medical accuracy issue: The management sequence is inverted. Minimal fix: Change the key to B, or add to the stem 'after failed percutaneous drainage' to justify surgical intervention.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-002", "question": "A 62-year-old woman with chronic lymphocytic leukemia develops petechiae and easy bruising. Laboratory studies show hemoglobin 9.2 g/dL, platelets 12,000/μL, and white blood cells 45,000/μL with 80% lymphocytes. Bone marrow biopsy reveals 90% infiltration by small lymphocytes. She has no active infection or bleeding. What is the most likely mechanism underlying her thrombocytopenia?", "options": ["Autoimmune destruction mediated by anti-platelet antibodies", "Bone marrow suppression from leukemic infiltration", "Hypersplenism with platelet sequestration", "Drug-induced thrombocytopenia from prior chemotherapy", "Microangiopathic hemolytic anemia with consumptive thrombocytopenia"], "answer": "B", "answer_index": 1, "explanation": "In advanced chronic lymphocytic leukemia, thrombocytopenia is primarily due to bone marrow infiltration by leukemic cells, crowding out normal hematopoiesis. Autoimmune thrombocytopenia occurs in only 1-2% of cases and typically responds to steroids, while hypersplenism is less common without massive splenomegaly. Drug effects or microangiopathy are not supported by the clinical scenario.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a CLL patient with severe thrombocytopenia (12,000/μL) and 90% marrow infiltration. Key discriminating findings: petechiae/bruising, severe thrombocytopenia, 90% marrow infiltration, no infection/bleeding. The question asks for the \\\"most likely mechanism.\\\" Option B (marrow infiltration) is supported by the 90% infiltration finding. However, Option A (autoimmune ITP) is equally defensible: CLL-associated ITP is well-documented (occurs in 2-5% of CLL patients, not just 1-2%), can present with severe thrombocytopenia and petechiae, and the vignette does NOT exclude it—no mention of prior steroid trial, direct antiglobulin test, or platelet antibody testing. The stem lacks critical discriminating data (spleen size for Option C, medication history for Option D, schistocytes/hemolysis markers for Option E). Medical accuracy issue: The rationale understates ITP prevalence in CLL and oversimplifies causation—both marrow replacement AND immune destruction can coexist or dominate. In advanced CLL with 90% infiltration, marrow failure is plausible, but isolated severe thrombocytopenia with only mild anemia (Hgb 9.2) is atypical for pure marrow failure, raising suspicion for immune-mediated component. Minimal fix: Add \\\"splenomegaly absent, no prior chemotherapy, negative direct antiglobulin test\\\" to exclude A and C definitively, or rephrase to ask for \\\"mechanism supported by bone marrow findings.\\\"\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a CLL patient with severe thrombocytopenia (12,000/μL) and 90% marrow infiltration. Key discriminating findings: petechiae/bruising, severe thrombocytopenia, 90% marrow infiltration, no infection/bleeding. The question asks for the \"most likely mechanism.\" Option B (marrow infiltration) is supported by the 90% infiltration finding. However, Option A (autoimmune ITP) is equally defensible: CLL-associated ITP is well-documented (occurs in 2-5% of CLL patients, not just 1-2%), can present with severe thrombocytopenia and petechiae, and the vignette does NOT exclude it—no mention of prior steroid trial, direct antiglobulin test, or platelet antibody testing. The stem lacks critical discriminating data (spleen size for Option C, medication history for Option D, schistocytes/hemolysis markers for Option E). Medical accuracy issue: The rationale understates ITP prevalence in CLL and oversimplifies causation—both marrow replacement AND immune destruction can coexist or dominate. In advanced CLL with 90% infiltration, marrow failure is plausible, but isolated severe thrombocytopenia with only mild anemia (Hgb 9.2) is atypical for pure marrow failure, raising suspicion for immune-mediated component. Minimal fix: Add \"splenomegaly absent, no prior chemotherapy, negative direct antiglobulin test\" to exclude A and C definitively, or rephrase to ask for \"mechanism supported by bone marrow findings.\"", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-003", "question": "A 28-year-old man with common variable immunodeficiency presents with recurrent sinopulmonary infections. Immunoglobulin levels show IgG 150 mg/dL, IgA <5 mg/dL, and IgM 20 mg/dL. He has absent responses to protein and polysaccharide vaccines. Genetic testing reveals a heterozygous mutation in the TACI gene. What is the most appropriate long-term management strategy?", "options": ["Monthly intravenous immunoglobulin replacement", "Prophylactic antibiotics with trimethoprim-sulfamethoxazole", "Hematopoietic stem cell transplantation", "Rituximab therapy to deplete B cells", "Interleukin-2 supplementation"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin replacement is the cornerstone of therapy for common variable immunodeficiency to prevent infections by providing passive immunity. Prophylactic antibiotics are adjunctive but not sufficient alone, while transplantation is reserved for severe cases with cellular defects. Rituximab and IL-2 are not standard for this humoral immunodeficiency.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 28-year-old man with CVID (confirmed by severely low IgG <400 mg/dL, absent IgA, low IgM, and absent vaccine responses). Key discriminating findings: profound hypogammaglobulinemia (IgG 150 mg/dL, normal >700), recurrent sinopulmonary infections, and absent vaccine responses indicating humoral immunodeficiency. The TACI mutation is consistent with CVID genetics. The question asks for long-term management strategy. Option A (IVIG replacement) is the established standard of care for CVID, providing passive immunity to prevent infections—this directly addresses the underlying antibody deficiency. Option B (prophylactic antibiotics) is adjunctive but insufficient as monotherapy for severe hypogammaglobulinemia. Option C (HSCT) is reserved for CVID with severe complications (refractory cytopenias, malignancy, severe enteropathy), not first-line. Option D (rituximab) would worsen B-cell function. Option E (IL-2) addresses T-cell defects, not relevant here. The item is medically accurate, logically sound, and the key is defensible as the unique best answer. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 28-year-old man with CVID (confirmed by severely low IgG <400 mg/dL, absent IgA, low IgM, and absent vaccine responses). Key discriminating findings: profound hypogammaglobulinemia (IgG 150 mg/dL, normal >700), recurrent sinopulmonary infections, and absent vaccine responses indicating humoral immunodeficiency. The TACI mutation is consistent with CVID genetics. The question asks for long-term management strategy. Option A (IVIG replacement) is the established standard of care for CVID, providing passive immunity to prevent infections—this directly addresses the underlying antibody deficiency. Option B (prophylactic antibiotics) is adjunctive but insufficient as monotherapy for severe hypogammaglobulinemia. Option C (HSCT) is reserved for CVID with severe complications (refractory cytopenias, malignancy, severe enteropathy), not first-line. Option D (rituximab) would worsen B-cell function. Option E (IL-2) addresses T-cell defects, not relevant here. The item is medically accurate, logically sound, and the key is defensible as the unique best answer. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-004", "question": "A 35-year-old traveler returns from sub-Saharan Africa with fever, chills, and myalgias. Blood smear shows ring forms and gametocytes consistent with Plasmodium falciparum. He is treated with artemether-lumefantrine, but 48 hours later, parasitemia persists at 3%. Genotyping reveals a mutation in the PfKelch13 gene. What is the most appropriate next therapeutic intervention?", "options": ["Switch to atovaquone-proguanil", "Add primaquine for gametocytocidal effect", "Initiate intravenous artesunate", "Administer doxycycline as monotherapy", "Use mefloquine as alternative therapy"], "answer": "C", "answer_index": 2, "explanation": "Persistent parasitemia with PfKelch13 mutation indicates artemisinin resistance, necessitating intravenous artesunate for rapid parasite clearance in severe or resistant falciparum malaria. Atovaquone-proguanil or mefloquine may face cross-resistance, while primaquine and doxycycline are not first-line for acute treatment failure. Artesunate is recommended by WHO for such cases.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best option. Key stem clues: 35-year-old with P. falciparum, treated with artemether-lumefantrine, persistent 3% parasitemia at 48h, PfKelch13 mutation (artemisinin resistance). The question asks for next therapeutic intervention after treatment failure. Main logical issue: The keyed answer (C: IV artesunate) is inappropriate because artesunate is an artemisinin derivative, and the patient has documented artemisinin resistance (PfKelch13 mutation). Switching to another artemisinin would not address resistance. The best answer is A (atovaquone-proguanil), a non-artemisinin combination effective for artemisinin-resistant malaria. The rationale incorrectly states atovaquone-proguanil may face cross-resistance, but these drugs have different mechanisms and no cross-resistance with artemisinins. Main medical accuracy issue: The explanation contradicts standard management of artemisinin-resistant malaria. WHO guidelines recommend non-artemisinin alternatives (like atovaquone-proguanil) for confirmed artemisinin resistance, not switching to IV artesunate. The patient is stable (outpatient treatment initially), not requiring IV therapy for severe malaria. Minimal fix: Change key to A, or reframe vignette to describe severe malaria criteria (altered consciousness, high parasitemia >10%, organ dysfunction) where IV artesunate would be indicated despite resistance concerns.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best option. Key stem clues: 35-year-old with P. falciparum, treated with artemether-lumefantrine, persistent 3% parasitemia at 48h, PfKelch13 mutation (artemisinin resistance). The question asks for next therapeutic intervention after treatment failure. Main logical issue: The keyed answer (C: IV artesunate) is inappropriate because artesunate is an artemisinin derivative, and the patient has documented artemisinin resistance (PfKelch13 mutation). Switching to another artemisinin would not address resistance. The best answer is A (atovaquone-proguanil), a non-artemisinin combination effective for artemisinin-resistant malaria. The rationale incorrectly states atovaquone-proguanil may face cross-resistance, but these drugs have different mechanisms and no cross-resistance with artemisinins. Main medical accuracy issue: The explanation contradicts standard management of artemisinin-resistant malaria. WHO guidelines recommend non-artemisinin alternatives (like atovaquone-proguanil) for confirmed artemisinin resistance, not switching to IV artesunate. The patient is stable (outpatient treatment initially), not requiring IV therapy for severe malaria. Minimal fix: Change key to A, or reframe vignette to describe severe malaria criteria (altered consciousness, high parasitemia >10%, organ dysfunction) where IV artesunate would be indicated despite resistance concerns.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-005", "question": "A 55-year-old man with metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation progresses on osimertinib. Tumor biopsy shows transformation to small cell histology. He has good performance status. What is the most appropriate systemic therapy?", "options": ["Continue osimertinib with added chemotherapy", "Switch to amivantamab", "Initiate etoposide and platinum-based chemotherapy", "Use mobocertinib as targeted therapy", "Administer immune checkpoint inhibitor monotherapy"], "answer": "C", "answer_index": 2, "explanation": "Transformation to small cell lung cancer in EGFR-mutant NSCLC requires treatment as small cell carcinoma with etoposide-platinum chemotherapy, which has shown responses in such cases. Continuing EGFR inhibitors is ineffective post-transformation, while amivantamab and mobocertinib target specific exon 20 insertions but not small cell histology. Immunotherapy has limited efficacy in transformed disease.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a patient with EGFR-mutant NSCLC who has undergone histologic transformation to small cell lung cancer (SCLC) after progression on osimertinib. Key discriminating findings: (1) EGFR exon 20 insertion mutation, (2) progression on osimertinib, (3) transformation to small cell histology, (4) good performance status. The clinical problem is selecting appropriate systemic therapy for transformed SCLC. Option C (etoposide-platinum chemotherapy) is the established standard of care for SCLC, including transformation cases, as transformed SCLC behaves biologically like de novo SCLC and loses dependence on the original EGFR driver mutation. Option A is incorrect because EGFR inhibitors lose efficacy post-transformation. Option B (amivantamab) and D (mobocertinib) target EGFR exon 20 insertions but are ineffective against SCLC histology. Option E is suboptimal as immunotherapy monotherapy has limited efficacy in transformed SCLC compared to chemotherapy. The item is medically accurate, reflecting current oncology practice for histologic transformation. No logical flaws or ambiguities exist. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a patient with EGFR-mutant NSCLC who has undergone histologic transformation to small cell lung cancer (SCLC) after progression on osimertinib. Key discriminating findings: (1) EGFR exon 20 insertion mutation, (2) progression on osimertinib, (3) transformation to small cell histology, (4) good performance status. The clinical problem is selecting appropriate systemic therapy for transformed SCLC. Option C (etoposide-platinum chemotherapy) is the established standard of care for SCLC, including transformation cases, as transformed SCLC behaves biologically like de novo SCLC and loses dependence on the original EGFR driver mutation. Option A is incorrect because EGFR inhibitors lose efficacy post-transformation. Option B (amivantamab) and D (mobocertinib) target EGFR exon 20 insertions but are ineffective against SCLC histology. Option E is suboptimal as immunotherapy monotherapy has limited efficacy in transformed SCLC compared to chemotherapy. The item is medically accurate, reflecting current oncology practice for histologic transformation. No logical flaws or ambiguities exist. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-006", "question": "A 12-year-old boy with hereditary angioedema type I presents with recurrent abdominal pain and facial swelling. Laboratory studies show C1 inhibitor level 20% of normal and low C4. He has breakthrough episodes despite prophylactic danazol. What is the most appropriate escalation in therapy?", "options": ["Switch to tranexamic acid prophylaxis", "Initiate subcutaneous C1 inhibitor replacement", "Add icatibant for on-demand treatment", "Use ecallantide for acute attacks", "Administer fresh frozen plasma infusions"], "answer": "B", "answer_index": 1, "explanation": "Subcutaneous C1 inhibitor replacement is effective for prophylaxis in hereditary angioedema with breakthrough on androgens, providing targeted replacement of the deficient protein. Tranexamic acid is less effective for type I, while icatibant and ecallantide are for acute treatment, not prophylaxis. Fresh frozen plasma carries risks and is not preferred for long-term use.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 12-year-old with HAE type I (low C1-INH, low C4) experiencing breakthrough episodes despite danazol prophylaxis, asking for appropriate escalation. Key discriminating findings: (1) confirmed HAE type I with laboratory evidence, (2) inadequate control on current prophylaxis (danazol), (3) need for escalation of preventive therapy. The keyed answer (B: subcutaneous C1-INH replacement) is the appropriate next step for prophylaxis escalation in breakthrough HAE. Option A (tranexamic acid) is less effective than androgens for HAE type I prophylaxis, making it an illogical switch. Options C (icatibant) and D (ecallantide) are acute/on-demand treatments, not prophylaxis escalation. Option E (FFP) contains C1-INH but carries infection/volume risks and is not standard for long-term prophylaxis when purified C1-INH concentrates are available. The item is medically accurate: subcutaneous C1-INH (e.g., Haegarda, Berinert SC) is FDA-approved for routine prophylaxis and represents appropriate escalation when androgens fail. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 12-year-old with HAE type I (low C1-INH, low C4) experiencing breakthrough episodes despite danazol prophylaxis, asking for appropriate escalation. Key discriminating findings: (1) confirmed HAE type I with laboratory evidence, (2) inadequate control on current prophylaxis (danazol), (3) need for escalation of preventive therapy. The keyed answer (B: subcutaneous C1-INH replacement) is the appropriate next step for prophylaxis escalation in breakthrough HAE. Option A (tranexamic acid) is less effective than androgens for HAE type I prophylaxis, making it an illogical switch. Options C (icatibant) and D (ecallantide) are acute/on-demand treatments, not prophylaxis escalation. Option E (FFP) contains C1-INH but carries infection/volume risks and is not standard for long-term prophylaxis when purified C1-INH concentrates are available. The item is medically accurate: subcutaneous C1-INH (e.g., Haegarda, Berinert SC) is FDA-approved for routine prophylaxis and represents appropriate escalation when androgens fail. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-007", "question": "An 82-year-old woman with mild cognitive impairment presents with recurrent falls and orthostatic hypotension. She takes donepezil 10 mg daily. Autonomic testing shows sympathetic denervation. Brain MRI reveals hippocampal atrophy. What is the most likely underlying diagnosis contributing to her symptoms?", "options": ["Alzheimer disease with autonomic involvement", "Lewy body dementia", "Multiple system atrophy", "Vascular parkinsonism", "Progressive supranuclear palsy"], "answer": "B", "answer_index": 1, "explanation": "Lewy body dementia often presents with orthostatic hypotension due to autonomic dysfunction, recurrent falls, and cognitive impairment with hippocampal atrophy on MRI. Alzheimer disease rarely causes significant autonomic symptoms, while multiple system atrophy typically has more severe parkinsonism and cerebellar signs. Vascular parkinsonism and PSP lack prominent autonomic features.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes an 82-year-old woman with cognitive impairment, recurrent falls, orthostatic hypotension, sympathetic denervation on autonomic testing, and hippocampal atrophy on MRI. The question asks for the most likely diagnosis. Key issue: Both Lewy body dementia (LBD, option B) and multiple system atrophy (MSA, option C) present with prominent autonomic dysfunction and falls. The stem provides sympathetic denervation on autonomic testing—a finding consistent with both disorders. While the rationale states MSA has 'more severe parkinsonism and cerebellar signs,' the vignette does not specify absence of these features; it simply doesn't mention motor examination findings. Hippocampal atrophy can occur in both LBD and MSA, though more typical of LBD. The mild cognitive impairment and donepezil use favor LBD, but MSA can present with cognitive changes. Without explicit motor/cerebellar examination findings or more specific autonomic testing patterns (e.g., cardiac MIBG scan results), both B and C remain defensible. Medical accuracy: The keyed answer is medically plausible but not uniquely supported. Minimal fix: Add explicit statement of absent/minimal parkinsonism and cerebellar signs, or specify cardiac sympathetic denervation pattern typical of LBD versus MSA.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes an 82-year-old woman with cognitive impairment, recurrent falls, orthostatic hypotension, sympathetic denervation on autonomic testing, and hippocampal atrophy on MRI. The question asks for the most likely diagnosis. Key issue: Both Lewy body dementia (LBD, option B) and multiple system atrophy (MSA, option C) present with prominent autonomic dysfunction and falls. The stem provides sympathetic denervation on autonomic testing—a finding consistent with both disorders. While the rationale states MSA has 'more severe parkinsonism and cerebellar signs,' the vignette does not specify absence of these features; it simply doesn't mention motor examination findings. Hippocampal atrophy can occur in both LBD and MSA, though more typical of LBD. The mild cognitive impairment and donepezil use favor LBD, but MSA can present with cognitive changes. Without explicit motor/cerebellar examination findings or more specific autonomic testing patterns (e.g., cardiac MIBG scan results), both B and C remain defensible. Medical accuracy: The keyed answer is medically plausible but not uniquely supported. Minimal fix: Add explicit statement of absent/minimal parkinsonism and cerebellar signs, or specify cardiac sympathetic denervation pattern typical of LBD versus MSA.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-008", "question": "A 58-year-old man with IgA nephropathy and chronic kidney disease stage 4 develops hyperkalemia refractory to dietary restriction and loop diuretics. Serum potassium is 6.8 mEq/L with normal acid-base status. He is not on ACE inhibitors. What is the most appropriate pharmacologic intervention?", "options": ["Initiate sodium polystyrene sulfonate", "Start patiromer therapy", "Administer sodium zirconium cyclosilicate", "Use fludrocortisone acetate", "Prescribe sodium bicarbonate supplementation"], "answer": "D", "answer_index": 3, "explanation": "Fludrocortisone promotes potassium excretion in the distal tubule and is useful for hyperkalemia in hypoaldosteronism-like states in CKD without acidosis. Patiromer and zirconium are binders for chronic management but less effective in advanced CKD without dialysis. Polystyrene sulfonate has safety concerns, and bicarbonate is for acidotic states.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best option. The stem describes severe hyperkalemia (6.8 mEq/L) in CKD stage 4 that is refractory to standard measures. Key discriminating findings: K+ 6.8 mEq/L (dangerously elevated), CKD stage 4 (GFR 15-29), refractory to diet/diuretics, normal acid-base. The question asks for \\\"most appropriate pharmacologic intervention\\\" for this acute, severe hyperkalemia. Fludrocortisone (option D, the key) is a mineralocorticoid that enhances distal tubular potassium secretion but has slow onset (days) and limited efficacy in advanced CKD where nephron mass is severely reduced. It's rarely used for acute hyperkalemia management. Options B (patiromer) and C (sodium zirconium cyclosilicate) are newer potassium binders specifically approved for chronic hyperkalemia management in CKD, with zirconium cyclosilicate having faster onset and better evidence in advanced CKD. For K+ 6.8 mEq/L, either B or C would be more appropriate than fludrocortisone. The rationale incorrectly dismisses these binders as \\\"less effective in advanced CKD without dialysis\\\" - they are actually indicated for this scenario. Medical accuracy issue: fludrocortisone is not standard therapy for severe hyperkalemia in advanced CKD. Minimal fix: Change key to B or C, or reframe question to specify hypoaldosteronism with milder hyperkalemia.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best option. The stem describes severe hyperkalemia (6.8 mEq/L) in CKD stage 4 that is refractory to standard measures. Key discriminating findings: K+ 6.8 mEq/L (dangerously elevated), CKD stage 4 (GFR 15-29), refractory to diet/diuretics, normal acid-base. The question asks for \"most appropriate pharmacologic intervention\" for this acute, severe hyperkalemia. Fludrocortisone (option D, the key) is a mineralocorticoid that enhances distal tubular potassium secretion but has slow onset (days) and limited efficacy in advanced CKD where nephron mass is severely reduced. It's rarely used for acute hyperkalemia management. Options B (patiromer) and C (sodium zirconium cyclosilicate) are newer potassium binders specifically approved for chronic hyperkalemia management in CKD, with zirconium cyclosilicate having faster onset and better evidence in advanced CKD. For K+ 6.8 mEq/L, either B or C would be more appropriate than fludrocortisone. The rationale incorrectly dismisses these binders as \"less effective in advanced CKD without dialysis\" - they are actually indicated for this scenario. Medical accuracy issue: fludrocortisone is not standard therapy for severe hyperkalemia in advanced CKD. Minimal fix: Change key to B or C, or reframe question to specify hypoaldosteronism with milder hyperkalemia.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-009", "question": "A 40-year-old woman with sickle cell disease presents with acute chest syndrome. She has hypoxia, fever, and new infiltrates on chest X-ray. Hemoglobin is 6.5 g/dL, reticulocytes 12%. Transfusion is initiated, but she develops worsening dyspnea and hypertension. What is the most likely complication?", "options": ["Transfusion-related acute lung injury", "Hyperhemolysis syndrome", "Transfusion-associated circulatory overload", "Delayed hemolytic transfusion reaction", "Acute hemolytic reaction from alloantibodies"], "answer": "C", "answer_index": 2, "explanation": "Transfusion-associated circulatory overload is common in sickle cell patients with acute chest syndrome due to volume sensitivity and underlying cardiac strain, presenting with hypertension and dyspnea. TRALI typically involves hypotension, while hyperhemolysis shows hemolysis without volume overload. Delayed reactions occur later, and acute hemolysis presents with fever and back pain.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer (C, TACO) is not the best answer. Key stem clues: 40-year-old with sickle cell disease, acute chest syndrome, severe anemia (Hgb 6.5), high reticulocyte count (12%), develops worsening dyspnea and hypertension during transfusion. The critical discriminator is the sickle cell disease context with severe anemia and high reticulocyte count indicating active hemolysis. Hyperhemolysis syndrome (B) is a well-recognized, life-threatening complication in sickle cell patients receiving transfusions, characterized by paradoxical worsening anemia, hemolysis of both donor and recipient RBCs, and can present acutely with dyspnea. The rationale incorrectly dismisses hyperhemolysis as showing 'hemolysis without volume overload' – hyperhemolysis can present with acute respiratory distress. While TACO causes hypertension and dyspnea, it doesn't explain the sickle cell-specific risk profile or the baseline severe hemolysis (reticulocyte 12%). TRALI (A) typically causes hypotension, not hypertension. Delayed reactions (D) occur days later. Acute hemolytic reactions (E) present differently. Main logical issue: The keyed answer ignores the sickle cell-specific transfusion complication that best fits the clinical picture. Minimal fix: Change key to B (Hyperhemolysis syndrome) or add timing details that definitively exclude hyperhemolysis.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer (C, TACO) is not the best answer. Key stem clues: 40-year-old with sickle cell disease, acute chest syndrome, severe anemia (Hgb 6.5), high reticulocyte count (12%), develops worsening dyspnea and hypertension during transfusion. The critical discriminator is the sickle cell disease context with severe anemia and high reticulocyte count indicating active hemolysis. Hyperhemolysis syndrome (B) is a well-recognized, life-threatening complication in sickle cell patients receiving transfusions, characterized by paradoxical worsening anemia, hemolysis of both donor and recipient RBCs, and can present acutely with dyspnea. The rationale incorrectly dismisses hyperhemolysis as showing 'hemolysis without volume overload' – hyperhemolysis can present with acute respiratory distress. While TACO causes hypertension and dyspnea, it doesn't explain the sickle cell-specific risk profile or the baseline severe hemolysis (reticulocyte 12%). TRALI (A) typically causes hypotension, not hypertension. Delayed reactions (D) occur days later. Acute hemolytic reactions (E) present differently. Main logical issue: The keyed answer ignores the sickle cell-specific transfusion complication that best fits the clinical picture. Minimal fix: Change key to B (Hyperhemolysis syndrome) or add timing details that definitively exclude hyperhemolysis.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-010", "question": "A 50-year-old man with rheumatoid arthritis on methotrexate develops pancytopenia. Bone marrow biopsy shows hypocellularity with absent megakaryocytes. Autoantibody testing is negative. Genetic analysis reveals shortened telomeres and a TERT mutation. What is the most appropriate definitive treatment?", "options": ["Switch to alternative immunosuppressive therapy", "Initiate danazol for telomere elongation", "Perform allogeneic hematopoietic stem cell transplant", "Administer eltrombopag as thrombopoietin mimetic", "Use anti-thymocyte globulin with cyclosporine"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic stem cell transplant is curative for dyskeratosis congenita-related aplastic anemia due to telomere biology disorders, addressing the underlying genetic defect. Danazol may stabilize telomeres temporarily but is not definitive, while immunosuppressives like ATG are for acquired aplasia. Eltrombopag stimulates residual marrow but does not correct the genetic issue.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 50-year-old man with pancytopenia, hypocellular marrow with absent megakaryocytes, negative autoantibodies, shortened telomeres, and TERT mutation—classic for telomere biology disorder (dyskeratosis congenita spectrum). Key discriminating findings: (1) genetic confirmation of TERT mutation with shortened telomeres establishes inherited bone marrow failure, (2) negative autoantibodies excludes autoimmune/acquired aplastic anemia, (3) hypocellular marrow with absent megakaryocytes indicates severe aplasia. The question asks for \\\"definitive treatment.\\\" Option C (allogeneic HSCT) is the only curative therapy for inherited bone marrow failure syndromes, addressing the stem cell defect. Option A is incorrect—methotrexate may contribute but genetic defect is primary. Option B (danazol) may temporarily stabilize telomeres but is palliative, not definitive. Option D (eltrombopag) stimulates residual hematopoiesis but doesn't cure. Option E (ATG/cyclosporine) treats acquired aplastic anemia, inappropriate here given genetic etiology. The keyed answer is medically accurate and uniquely defensible. No logical flaws or missing critical details. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 50-year-old man with pancytopenia, hypocellular marrow with absent megakaryocytes, negative autoantibodies, shortened telomeres, and TERT mutation—classic for telomere biology disorder (dyskeratosis congenita spectrum). Key discriminating findings: (1) genetic confirmation of TERT mutation with shortened telomeres establishes inherited bone marrow failure, (2) negative autoantibodies excludes autoimmune/acquired aplastic anemia, (3) hypocellular marrow with absent megakaryocytes indicates severe aplasia. The question asks for \"definitive treatment.\" Option C (allogeneic HSCT) is the only curative therapy for inherited bone marrow failure syndromes, addressing the stem cell defect. Option A is incorrect—methotrexate may contribute but genetic defect is primary. Option B (danazol) may temporarily stabilize telomeres but is palliative, not definitive. Option D (eltrombopag) stimulates residual hematopoiesis but doesn't cure. Option E (ATG/cyclosporine) treats acquired aplastic anemia, inappropriate here given genetic etiology. The keyed answer is medically accurate and uniquely defensible. No logical flaws or missing critical details. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-011", "question": "A 25-year-old man with HIV on antiretroviral therapy presents with headache and seizures. CSF analysis shows lymphocytic pleocytosis, elevated protein, and positive India ink stain. MRI reveals multiple ring-enhancing lesions. CD4 count is 150 cells/μL. What is the most appropriate initial management?", "options": ["Start amphotericin B and flucytosine induction", "Initiate pyrimethamine and sulfadiazine", "Administer acyclovir for herpes encephalitis", "Use intravenous ceftriaxone for bacterial meningitis", "Prescribe albendazole for neurocysticercosis"], "answer": "A", "answer_index": 0, "explanation": "Cryptococcal meningitis in HIV presents with India ink-positive CSF and ring-enhancing lesions, requiring induction with amphotericin B and flucytosine for clearance. Toxoplasmosis lacks India ink positivity, while herpes, bacterial, and parasitic etiologies do not match the CSF findings. Prompt antifungal therapy reduces mortality in this setting.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: C (Contradiction). Verdict: No defensible answer. The vignette contains an internal contradiction that makes it unsolvable. Cryptococcal meningitis (indicated by positive India ink stain) does NOT typically present with ring-enhancing lesions on MRI—it shows meningeal enhancement, hydrocephalus, or cryptococcomas (non-ring-enhancing nodules). Ring-enhancing lesions in an HIV patient with CD4 150 cells/μL are classic for CNS toxoplasmosis. However, toxoplasmosis does not produce positive India ink stain (which specifically identifies Cryptococcus neoformans). The stem simultaneously points to two different diagnoses with mutually exclusive findings: India ink positivity demands cryptococcal meningitis (answer A: amphotericin B + flucytosine), while ring-enhancing lesions demand toxoplasmosis (answer B: pyrimethamine + sulfadiazine). This creates an irreconcilable contradiction. Medical accuracy issue: The vignette conflates diagnostic features of two distinct entities. Minimal fix: Remove either the India ink positivity (making it pure toxoplasmosis, key B) OR change ring-enhancing lesions to meningeal enhancement/cryptococcomas (making it pure cryptococcal meningitis, key A). As written, the item is internally inconsistent and unsolvable.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (Contradiction). Verdict: No defensible answer. The vignette contains an internal contradiction that makes it unsolvable. Cryptococcal meningitis (indicated by positive India ink stain) does NOT typically present with ring-enhancing lesions on MRI—it shows meningeal enhancement, hydrocephalus, or cryptococcomas (non-ring-enhancing nodules). Ring-enhancing lesions in an HIV patient with CD4 150 cells/μL are classic for CNS toxoplasmosis. However, toxoplasmosis does not produce positive India ink stain (which specifically identifies Cryptococcus neoformans). The stem simultaneously points to two different diagnoses with mutually exclusive findings: India ink positivity demands cryptococcal meningitis (answer A: amphotericin B + flucytosine), while ring-enhancing lesions demand toxoplasmosis (answer B: pyrimethamine + sulfadiazine). This creates an irreconcilable contradiction. Medical accuracy issue: The vignette conflates diagnostic features of two distinct entities. Minimal fix: Remove either the India ink positivity (making it pure toxoplasmosis, key B) OR change ring-enhancing lesions to meningeal enhancement/cryptococcomas (making it pure cryptococcal meningitis, key A). As written, the item is internally inconsistent and unsolvable.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-012", "question": "A 65-year-old woman with triple-negative breast cancer metastatic to liver and bones receives paclitaxel. After the third cycle, she develops grade 3 neuropathy and pancytopenia. Germline testing reveals a PALB2 mutation. What is the most appropriate adjustment to her treatment regimen?", "options": ["Switch to eribulin monotherapy", "Add olaparib as PARP inhibitor", "Initiate sacituzumab govitecan", "Use capecitabine as oral chemotherapy", "Administer talazoparib with dose reduction"], "answer": "B", "answer_index": 1, "explanation": "PALB2 mutations confer sensitivity to PARP inhibitors like olaparib in metastatic breast cancer, offering a targeted approach after chemotherapy toxicity. Eribulin and capecitabine are chemotherapies without targeting the mutation, while sacituzumab is for later lines. Talazoparib is another PARP but not first-choice here.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient with germline PALB2-mutated metastatic triple-negative breast cancer (TNBC) who develops severe toxicity (grade 3 neuropathy, pancytopenia) after paclitaxel. Key discriminating findings: PALB2 mutation (PARP inhibitor sensitivity), severe chemotherapy toxicity requiring regimen change, metastatic TNBC. The question asks for the \\\"most appropriate adjustment.\\\" Option B (add olaparib) and Option E (talazoparib with dose reduction) are both PARP inhibitors appropriate for PALB2-mutated breast cancer. The rationale dismisses talazoparib as \\\"not first-choice\\\" without justification—both olaparib and talazoparib are FDA-approved for germline BRCA/PALB2-mutated HER2-negative metastatic breast cancer. The stem does not specify prior lines of therapy or provide criteria to prefer one PARP inhibitor over another. \\\"Add olaparib\\\" (B) vs. monotherapy talazoparib (E) both target the mutation; the choice between adding vs. switching and between specific agents requires unstated assumptions about treatment sequencing. Main logical issue: Two PARP inhibitor options are equally defensible without additional context. Medical accuracy: Both options align with guidelines. Minimal fix: Specify prior treatment lines or explicitly state why one PARP inhibitor is preferred, or remove one PARP option.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient with germline PALB2-mutated metastatic triple-negative breast cancer (TNBC) who develops severe toxicity (grade 3 neuropathy, pancytopenia) after paclitaxel. Key discriminating findings: PALB2 mutation (PARP inhibitor sensitivity), severe chemotherapy toxicity requiring regimen change, metastatic TNBC. The question asks for the \"most appropriate adjustment.\" Option B (add olaparib) and Option E (talazoparib with dose reduction) are both PARP inhibitors appropriate for PALB2-mutated breast cancer. The rationale dismisses talazoparib as \"not first-choice\" without justification—both olaparib and talazoparib are FDA-approved for germline BRCA/PALB2-mutated HER2-negative metastatic breast cancer. The stem does not specify prior lines of therapy or provide criteria to prefer one PARP inhibitor over another. \"Add olaparib\" (B) vs. monotherapy talazoparib (E) both target the mutation; the choice between adding vs. switching and between specific agents requires unstated assumptions about treatment sequencing. Main logical issue: Two PARP inhibitor options are equally defensible without additional context. Medical accuracy: Both options align with guidelines. Minimal fix: Specify prior treatment lines or explicitly state why one PARP inhibitor is preferred, or remove one PARP option.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-013", "question": "A 4-year-old girl with Wiskott-Aldrich syndrome presents with eczema, thrombocytopenia, and recurrent infections. She has low IgM and elevated IgE. Hematopoietic stem cell transplant is planned, but she develops hives after platelet transfusion. What is the most likely immunologic mechanism?", "options": ["IgA deficiency leading to anti-IgA antibodies", "Type I hypersensitivity to platelet antigens", "Complement activation by immune complexes", "IgE-mediated reaction to plasma proteins", "Delayed T-cell mediated hypersensitivity"], "answer": "D", "answer_index": 3, "explanation": "Elevated IgE in Wiskott-Aldrich syndrome predisposes to allergic reactions, including IgE-mediated hives from plasma proteins in transfusions. IgA deficiency is not typical, while type I hypersensitivity to antigens is less specific. Complement or T-cell mechanisms do not explain acute urticaria.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 4-year-old with Wiskott-Aldrich syndrome (WAS) who develops hives after platelet transfusion. Key clues: elevated IgE, acute urticarial reaction post-transfusion. The question asks for the immunologic mechanism. Option D (IgE-mediated reaction to plasma proteins) is keyed as correct, citing elevated IgE in WAS predisposing to allergic reactions. However, Option B (Type I hypersensitivity to platelet antigens) is equally defensible—hives after platelet transfusion classically represent Type I hypersensitivity, and the stem provides no evidence distinguishing whether the allergen is plasma proteins versus platelet-associated antigens. Both B and D describe IgE-mediated (Type I) mechanisms; the distinction between 'platelet antigens' and 'plasma proteins' cannot be determined from the vignette alone. The rationale dismisses B as 'less specific,' but this is arbitrary—both are Type I reactions, and platelet products contain both components. Medical accuracy: WAS patients do have elevated IgE and atopy risk, making allergic transfusion reactions plausible (score 4). Minimal fix: Specify clinical or laboratory evidence (e.g., 'reaction occurs with washed platelets' favoring plasma proteins, or 'HLA antibodies detected' favoring platelet antigens) to discriminate B from D.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 4-year-old with Wiskott-Aldrich syndrome (WAS) who develops hives after platelet transfusion. Key clues: elevated IgE, acute urticarial reaction post-transfusion. The question asks for the immunologic mechanism. Option D (IgE-mediated reaction to plasma proteins) is keyed as correct, citing elevated IgE in WAS predisposing to allergic reactions. However, Option B (Type I hypersensitivity to platelet antigens) is equally defensible—hives after platelet transfusion classically represent Type I hypersensitivity, and the stem provides no evidence distinguishing whether the allergen is plasma proteins versus platelet-associated antigens. Both B and D describe IgE-mediated (Type I) mechanisms; the distinction between 'platelet antigens' and 'plasma proteins' cannot be determined from the vignette alone. The rationale dismisses B as 'less specific,' but this is arbitrary—both are Type I reactions, and platelet products contain both components. Medical accuracy: WAS patients do have elevated IgE and atopy risk, making allergic transfusion reactions plausible (score 4). Minimal fix: Specify clinical or laboratory evidence (e.g., 'reaction occurs with washed platelets' favoring plasma proteins, or 'HLA antibodies detected' favoring platelet antigens) to discriminate B from D.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed131", "question_id": "20251216T182308874Z_grok-4-0709_seed131-014", "question": "A 78-year-old man with frailty and multimorbidity is admitted for pneumonia. He has a history of recurrent Clostridium difficile infections. Stool testing is positive for toxin. He completed vancomycin taper 2 weeks ago. What is the most appropriate treatment considering his geriatric status?", "options": ["Repeat oral vancomycin course", "Initiate fidaxomicin therapy", "Administer bezlotoxumab infusion", "Perform fecal microbiota transplant", "Use metronidazole as alternative"], "answer": "C", "answer_index": 2, "explanation": "Bezlotoxumab, a monoclonal antibody against C. difficile toxin B, reduces recurrence in high-risk elderly patients without altering gut flora, ideal for frail geriatrics. Fidaxomicin is effective but costly, while repeat vancomycin increases resistance risk. Transplant is invasive, and metronidazole is inferior for recurrences.", "generator_model": "grok-4-0709", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the most appropriate treatment. Key stem clues: 78-year-old frail patient with multimorbidity, recurrent C. difficile infection (at least second recurrence), completed vancomycin taper 2 weeks ago, now toxin-positive. The clinical problem is managing recurrent CDI in a high-risk geriatric patient. For recurrent CDI after vancomycin failure, current guidelines (IDSA/SHEA 2021) recommend fidaxomicin as first-line therapy for first recurrence, with FMT or fidaxomicin for second/subsequent recurrences. Bezlotoxumab (option C) is an adjunctive therapy used alongside antibiotics to prevent further recurrence, not a standalone treatment for active infection. The patient has active toxin-positive disease requiring antimicrobial therapy. Option B (fidaxomicin) is the most appropriate primary treatment – superior efficacy in preventing recurrence compared to vancomycin, especially in elderly/high-risk patients. Option A (repeat vancomycin) is reasonable but inferior to fidaxomicin for recurrent disease. The rationale incorrectly positions bezlotoxumab as primary therapy when it must be given with antibiotics. Main logical issue: the key identifies an adjunctive agent rather than definitive treatment. Minimal fix: Change key to B (fidaxomicin) or reframe question to ask about adjunctive therapy to prevent future recurrence.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the most appropriate treatment. Key stem clues: 78-year-old frail patient with multimorbidity, recurrent C. difficile infection (at least second recurrence), completed vancomycin taper 2 weeks ago, now toxin-positive. The clinical problem is managing recurrent CDI in a high-risk geriatric patient. For recurrent CDI after vancomycin failure, current guidelines (IDSA/SHEA 2021) recommend fidaxomicin as first-line therapy for first recurrence, with FMT or fidaxomicin for second/subsequent recurrences. Bezlotoxumab (option C) is an adjunctive therapy used alongside antibiotics to prevent further recurrence, not a standalone treatment for active infection. The patient has active toxin-positive disease requiring antimicrobial therapy. Option B (fidaxomicin) is the most appropriate primary treatment – superior efficacy in preventing recurrence compared to vancomycin, especially in elderly/high-risk patients. Option A (repeat vancomycin) is reasonable but inferior to fidaxomicin for recurrent disease. The rationale incorrectly positions bezlotoxumab as primary therapy when it must be given with antibiotics. Main logical issue: the key identifies an adjunctive agent rather than definitive treatment. Minimal fix: Change key to B (fidaxomicin) or reframe question to ask about adjunctive therapy to prevent future recurrence.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}]